RECENT COMMENTS

Rajesh Kumar: Is it helpfull for Overian cancer patient at advance stage? Rajesh Kumar +919681303310   »Read more

Cindy: I'm not a medical professional. My mother has been diagnosed with CUP - and was treated several year [...]   »Read more

Rajesh Kumar: +919681303310.   »Read more

Rajesh Kumar: Please write your comment here   »Read more

christian: Is gabapentin has been proposed to treat peripheric neuropathy induced by chemotherapy. At low dosa [...]   »Read more

 

Article type: Drug Watch

Keywords: Healthcare rationing, QALY, NICE, IQWiG, .

This article has 0 comments

Facebook Twitter Share - Send - Print - Pdf

 

Healthcare rationing: the moral dilemma

Healthcare rationing:
the moral dilemma

If Europe is to ensure that the latest therapies can be made available to all cancer patients who might benefit, getting maximum value from every euro spent on health will be essential. But who is to adjudicate that one patient can’t have something they need, because another with different needs could derive greater benefit for the same money?

» Anna Wagstaff


To read the complete article please click on the pdf icon
 
COMMENTS (0)
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.

ESO reserves the absolute right not to publish comments.
  Name (required)
  E-mail (will not be published) (required)
  Captcha code (required)

CancerWorld invites you to visit:

 
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, Celgene, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck Serono, Novartis, Roche and Sanofi Aventis.